|Videos|October 21, 2015
Side Effects Associated With Gleevec for GIST
Advertisement
Melissa Shepherd, an acute care nurse practitioner from the Huntsman Cancer Institute in Salt Lake City, Utah, discusses side effects associated with treatment for gastrointestinal stromal tumors (GIST).
The most common side effect with Gleevec (imatinib) is fatigue. To combat this fatigue, Shepherd says, patients should stay active, maintain a healthy diet and consider taking the drug at night.
Shepherd says nausea, edema, rash, diarrhea and thyroid issues can all also occur.
Advertisement
Related to this article
ASTRO’s first bladder cancer radiation guideline supports trimodal therapy as an alternative to bladder removal for select patients with muscle-invasive disease.
Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.
In a trial of 2,175 people with early HER2-positive breast cancer, 43.8% had no invasive cancer left after 12 weeks of a lighter regimen, and certain tumor features predicted who was most likely to respond.
Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo plus Herceptin and Perjeta.
A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.
In a study of more than 250,000 older adults presented at ASTRO 2026, people with depression who started talk therapy within a week of their cancer diagnosis had a 27% lower risk of dying from their cancer. But most people with depression received no mental health treatment at all.
Epkinly plus R-CHOP lowered the risk of disease progression or death by 51% versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma.
Living with incurable small lymphocytic lymphoma means facing new health challenges and fears while finding a balance between caution, optimism and daily life.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Tukysa Combination as Maintenance for HER2-Positive Breast Cancer
2
Living With Incurable Cancer: The Emotional Toll of Never Knowing What Comes Next
3
Lung Cancer Drug Misses Trial Goal, but Shows Fewer Side Effects
4
Early Depression Treatment May Be Linked to Lower Cancer Death Risk
5